2-[carbamimidoyl (methyl) amino] acetic acid

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• amyotrophic lateral sclerosis [Possibly Ineffective]
• arsenic poisoning [Insufficient Evidence]
• athletic performance [Possibly Effective]
• cerebral creatine deficiency syndromes [Possibly Effective]
• CHF [Insufficient Evidence]
• CKD [Insufficient Evidence]
• cognitive decline, age-related [Insufficient Evidence]
• cognitive function [Insufficient Evidence]
• COPD [Insufficient Evidence]
• depression [Insufficient Evidence]
• diabetes mellitus, type 2 [Insufficient Evidence]
• fatigue [Insufficient Evidence]
• fatigue, post-stroke [Insufficient Evidence]
• fibromyalgia [Insufficient Evidence]
• gyrate atrophy [Insufficient Evidence]
• hereditary motor and sensory neuropathy [Insufficient Evidence]
• Huntington dz [Possibly Ineffective]
• hyperhomocysteinemia [Insufficient Evidence]
• idiopathic inflammatory myopathies [Insufficient Evidence]
• juvenile idiopathic arthritis [Insufficient Evidence]
• McArdle dz [Insufficient Evidence]
• memory [Insufficient Evidence]
• mitochondrial myopathies [Insufficient Evidence]
• multiple sclerosis [Insufficient Evidence]
• muscle breakdown [Insufficient Evidence]
• muscle cramps [Insufficient Evidence]
• muscle strength [Possibly Effective]
• muscle wasting, HIV/AIDS-related [Insufficient Evidence]
• muscular dystrophy [Insufficient Evidence]
• neonatal apnea [Insufficient Evidence]
• osteoarthritis [Insufficient Evidence]
• osteopenia [Possibly Ineffective]
• Parkinson dz [Insufficient Evidence]
• peripheral arterial dz [Insufficient Evidence]
• postop recovery [Insufficient Evidence]
• Rett syndrome [Insufficient Evidence]
• rheumatoid arthritis [Insufficient Evidence]
• sarcopenia [Possibly Effective]
• schizophrenia [Insufficient Evidence]
• skin aging [Insufficient Evidence]
• spinal cord injury [Insufficient Evidence]
• spinal muscular atrophy [Insufficient Evidence]
• traumatic brain injury [Insufficient Evidence]